ARCHIVES

As Amgen, Johnson & Johnson Battle Over Anemia Market, Medicare Enters The Fray

This article is from The Cancer Letter archive.

Vol. 28 No. 46 | December 13, 2002

Download PDF Visit The Full Archive

Related Articles

NIH Defines Misconduct

December 9, 1994

After ODAC: Questions On ESA Claims, Advertising, Reimbursement Gain Urgency.

May 18, 2007

Olaparib, A PARP Inhibitor, Can Reduce Tumor Size In Advanced Ovarian Cancer

August 27, 2010

Broder’s Conundrum: How To Let Congress Know NCI Needs More Money Without Asking For it

March 17, 1989

Heavy Smokers And Drinkers Have Different Brain Chemistry

May 30, 2003

NCI Considers Seeking New Study Section For Clinical Research, Or Expansion Of E2

November 23, 1990